The Temple Thrombosis Research Center is a formally established research institute within the medical school dedicated to advancing our understanding of the etiology, pathogenesis, diagnosis and treatment of arterial and venous thrombosis. Investigators in this Center are examining the role of platelets, plasma coagulation factors, vascular wall cells, megakaryocytes and leukocytes in thrombogenesis. As normal biochemical and physiological mechanisms are elucidated, departures from these patterns of response provide the knowledge of pathological processes that are necessary for development of appropriate diagnostic tests. The increasing understanding of the abnormalities underlying the thrombotic process makes possible the rational development of therapeutic interventions to inhibit or prevent thrombogenesis in a vessel. Each project has the potential to indicate an appropriate inhibitory drug or other therapeutic approaches to prevent platelet aggregation, fibrin formation or the consequences of vessel wall injury, all of which contribute to the formation of an obstructing thrombus. The first objective is to understand the metabolism and eventually control stimulus-response coupling in platelets. The second objective is to study the interaction of plasma and platelet proteins with cells and surfaces in order to delineate mechanisms of the thrombotic process.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL036579-04
Application #
3098511
Study Section
Heart, Lung, and Blood Research Review Committee B (HLBB)
Project Start
1986-09-30
Project End
1991-09-29
Budget Start
1989-09-30
Budget End
1990-09-29
Support Year
4
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Temple University
Department
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Ahmad, S S; Rawala, R; Cheung, W F et al. (1995) The role of the second growth-factor domain of human factor IXa in binding to platelets and in factor-X activation. Biochem J 310 ( Pt 2):427-31
Wyshock, E G; Stewart, G J; Colman, R W (1994) Thrombin-stimulated human platelets express molecular forms of alpha-granule factor V (FV), which differ from FVa. Thromb Haemost 72:947-56
DeLa Cadena, R A; Wyshock, E G; Kunapuli, S P et al. (1994) Platelet thrombospondin interactions with human high and low molecular weight kininogens. Thromb Haemost 72:125-31
Ashby, B (1994) Interactions among prostaglandin receptors. Receptor 4:31-42
Pixley, R A; De La Cadena, R; Page, J D et al. (1993) The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 91:61-8
Walsh, P N; Baglia, F A; Jameson, B A (1993) Factor XI: structure-function relationships utilizing monoclonal antibodies protein modification, computational chemistry, and rational synthetic peptide design. Methods Enzymol 222:65-96
Ryan, R R; Daniel, J L; Cowan, A (1993) Two bombesin analogues discriminate between neuromedin B- and bombesin-induced calcium flux in a lung cancer cell line. Peptides 14:1231-5
Cook, J J; Trybulec, M; Lasz, E C et al. (1992) Binding of glycoprotein IIIa-derived peptide 217-231 to fibrinogen and von Willebrand factors and its inhibition by platelet glycoprotein IIb/IIIa complex. Biochim Biophys Acta 1119:312-21
Walsh, P N (1992) Factor XI: a renaissance. Semin Hematol 29:189-201
Shigeta, O; Gluszko, P; Downing, S W et al. (1992) Protection of platelets during long-term extracorporeal membrane oxygenation in sheep with a single dose of a disintegrin. Circulation 86:II398-404

Showing the most recent 10 out of 92 publications